Equities

Ascendis Pharma A/S

Ascendis Pharma A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)135.10
  • Today's Change-2.35 / -1.71%
  • Shares traded587.05k
  • 1 Year change+55.34%
  • Beta0.5916
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

  • Revenue in USD (TTM)356.70m
  • Net income in USD-543.75m
  • Incorporated2006
  • Employees879.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revolution Medicines Inc4.57m-484.27m6.32bn411.00--3.66--1,385.00-3.76-3.760.03510.460.0031--2.2912,079.37-32.48-29.76-34.18-32.59-----10,606.04-606.93----0.00---67.27-10.50-75.46--38.82--
Blueprint Medicines Corp282.21m-288.29m6.61bn645.00--21.27--23.42-4.82-4.824.594.960.24990.35316.18430,853.40-25.53-29.92-30.68-34.0696.97---102.15-116.653.61-23.370.4352--22.2241.149.06--4.85--
Jazz Pharmaceuticals PLC3.84bn330.79m6.63bn2.80k21.711.796.781.734.854.8555.4958.650.34360.64285.781,372,634.002.991.483.361.6289.5388.798.694.261.901.870.6070.004.7815.19285.14-1.49-20.04--
Viking Therapeutics Inc0.00-93.72m6.87bn28.00--7.35-----0.9305-0.93050.008.470.00----0.00-16.76-21.91-17.52-23.04------------0.00-------24.73------
Intra-Cellular Therapies Inc513.93m-110.87m7.10bn610.00--10.93--13.81-1.15-1.155.346.150.69961.674.83842,508.20-15.09-38.27-17.67-42.7792.82---21.57-128.425.00--0.00--85.51--45.49---7.22--
Legend Biotech Corp (ADR)342.80m-465.95m7.29bn1.80k--6.27--21.28-2.60-2.601.906.390.22979.52203.86190,443.30-31.22-37.71-37.33-47.1952.35---135.92-286.515.57-24.440.2233--143.7042.15-16.11--1.57--
Cerevel Therapeutics Holdings Inc0.00-460.47m7.42bn355.00--13.13-----2.72-2.720.003.100.00----0.00-44.76---48.20--------------0.3745-------23.14------
Bellring Brands Inc1.84bn191.50m7.59bn420.0040.45--32.084.121.441.4413.84-1.902.405.408.714,389,286.0024.9118.8931.72--32.7432.4410.3910.101.845.071.420.0021.5315.03101.0913.80-18.48--
Vaxcyte Inc0.00-436.82m7.65bn254.00--3.85-----4.22-4.220.0018.240.00----0.00-28.19-34.22-29.52-37.21------------0.00-------80.00--107.28--
Roivant Sciences Ltd124.80m4.35bn7.65bn845.002.041.401.8061.335.075.070.15717.400.0260.81872.97147,686.4088.04--103.92--87.53--3,390.53--25.10--0.0642--103.65--487.06------
Ascendis Pharma A/S (ADR)356.70m-543.75m7.87bn879.00------22.05-9.63-9.636.31-4.430.3720.246911.50405,796.80-56.71-47.35-130.03-53.2985.61---152.44-602.660.540-2.731.55--421.2090.6817.45---1.61--
Repligen Corp607.45m14.84m8.33bn1.78k590.644.2298.6313.710.25240.252410.7435.290.22551.434.87340,689.800.5514.380.61795.0347.7355.432.4415.915.24--0.22840.00-20.3126.91-77.6420.1324.99--
Exact Sciences Corp2.53bn-240.23m8.39bn6.50k--2.67--3.31-1.32-1.3213.9317.040.39985.2811.96389,975.40-3.79-9.71-4.13-10.6073.6774.10-9.48-28.211.45--0.4323--19.9340.6367.26---3.71--
Elanco Animal Health Inc4.37bn-1.30bn8.74bn9.30k--1.44--2.00-2.64-2.648.8412.260.29311.214.28469,354.80-8.74-3.27-9.65-3.6555.2854.28-29.83-11.531.960.8530.4877--0.1367.57-1,478.21--2.74--
KBR Inc7.07bn-258.00m8.82bn34.00k--6.28--1.25-1.91-1.9152.6710.461.25--5.56207,970.60-4.450.4725-6.460.667813.8612.18-3.580.4122--1.170.5678340.005.977.20-240.21--36.3111.03
Insmed Inc315.49m-746.89m8.98bn912.00------28.45-5.23-5.232.20-3.130.23570.89719.32345,936.40-55.80-40.96-72.23-46.8878.0777.99-236.74-212.921.61-16.081.64--24.3998.78-55.66---2.15--
Data as of May 31 2024. Currency figures normalised to Ascendis Pharma A/S's reporting currency: US Dollar USD

Institutional shareholders

71.78%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 31 Mar 202410.11m17.52%
Artisan Partners LPas of 31 Mar 20245.67m9.83%
Fidelity Management & Research Co. LLCas of 31 Mar 20244.61m7.99%
Westfield Capital Management Co. LPas of 31 Mar 20244.08m7.06%
Avoro Capital Advisor LLCas of 31 Mar 20243.97m6.87%
Janus Henderson Investors US LLCas of 31 Mar 20243.70m6.42%
Wellington Management Co. LLPas of 31 Mar 20242.75m4.76%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20242.57m4.45%
Capital Research & Management Co. (International Investors)as of 31 Mar 20242.19m3.80%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20241.78m3.09%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.